Payment overview · 2025
General Payments
$290.59
10 reported records · 5 companies
Healthcare provider profile · identity verified
Keri E Dillon, APRN, FNP-C
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Primary Care · OMAHA, NE · NPI 1093196909
Verified facts
What the public records show
CMS Open Payments records show Keri E Dillon, APRN, FNP-C received $290.59 in general payments during 2025 across 10 reported records.
ABBVIE INC. accounted for 53.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Synthroid by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $154.47 | 53.2% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $59.97 | 20.6% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $44.43 | 15.3% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.98 | 5.5% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $15.74 | 5.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $290.59 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $154.47 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $44.43 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $44.43 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $29.47 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $22.51 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.98 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $15.74 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 54 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
54 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 372 | 101 |
| Levothyroxine Sodium | Levothyroxine Sodium | 291 | 72 |
| Atorvastatin Calcium | Atorvastatin Calcium | 232 | 60 |
| Metoprolol Succinate | Metoprolol Succinate | 213 | 52 |
| Lisinopril | Lisinopril | 201 | 58 |
| Losartan Potassium | Losartan Potassium | 201 | 54 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 176 | 49 |
| Omeprazole | Omeprazole | 173 | 50 |
| Meloxicam | Meloxicam | 134 | 40 |
| Trazodone Hcl | Trazodone Hcl | 116 | 32 |
| Pantoprazole Sodium | Pantoprazole Sodium | 115 | 33 |
| Tramadol Hcl | Tramadol Hcl | 108 | 25 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 107 | 13 |
| Famotidine | Famotidine | 106 | 28 |
| Hydrochlorothiazide | Hydrochlorothiazide | 104 | 29 |
| Sertraline Hcl | Sertraline Hcl | 95 | 26 |
| Simvastatin | Simvastatin | 90 | 26 |
| Escitalopram Oxalate | Escitalopram Oxalate | 87 | 19 |
| Montelukast Sodium | Montelukast Sodium | 79 | 22 |
| Prednisone | Prednisone | 78 | 41 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 73 | 22 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 72 | 48 |
| Gabapentin | Gabapentin | 71 | 25 |
| Metformin Hcl | Metformin Hcl | 71 | 21 |
| Lorazepam | Lorazepam | 63 | 14 |
| Tamsulosin Hcl | Tamsulosin Hcl | 61 | 19 |
| Allopurinol | Allopurinol | 59 | 16 |
| Alprazolam | Alprazolam | 55 | 15 |
| Eliquis | Apixaban | 54 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 54 | 13 |
| Metformin Hcl Er | Metformin Hcl | 53 | 16 |
| Atenolol | Atenolol | 51 | 12 |
| Glimepiride | Glimepiride | 51 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 51 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 50 | 20 |
| Azithromycin | Azithromycin | 50 | 41 |
| Quetiapine Fumarate | Quetiapine Fumarate | 48 | suppressed |
| Glipizide Er | Glipizide | 47 | 14 |
| Amoxicillin | Amoxicillin | 43 | 33 |
| Furosemide | Furosemide | 42 | 16 |
| Doxazosin Mesylate | Doxazosin Mesylate | 41 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 41 | 34 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 40 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 39 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 39 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 39 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 37 | 11 |
| Potassium Chloride | Potassium Chloride | 36 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 34 | 16 |
| Diazepam | Diazepam | 34 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 34 | 15 |
| Donepezil Hcl | Donepezil Hcl | 32 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 31 | suppressed |
| Spironolactone | Spironolactone | 30 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 27 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 27 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 26 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 26 | 22 |
| Naproxen | Naproxen | 25 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 25 | 19 |
| Valsartan | Valsartan | 25 | suppressed |
| Myrbetriq | Mirabegron | 24 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 24 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 23 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 23 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 23 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 19 |
| Cefdinir | Cefdinir | 22 | 15 |
| Jardiance | Empagliflozin | 22 | suppressed |
| Pregabalin | Pregabalin | 22 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 21 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 21 | suppressed |
| Trimethoprim | Trimethoprim | 21 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 20 | suppressed |
| Cephalexin | Cephalexin | 20 | 18 |
| Clonazepam | Clonazepam | 20 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 20 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 20 | suppressed |
| Ozempic | Semaglutide | 20 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 20 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 19 | suppressed |
| Synthroid | Levothyroxine Sodium | 19 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 18 | suppressed |
| Celecoxib | Celecoxib | 18 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 17 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Memantine Hcl | Memantine Hcl | 16 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 16 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Xarelto | Rivaroxaban | 16 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 15 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | suppressed |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Baclofen | Baclofen | 14 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Bupropion Xl | Bupropion Hcl | 11 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 11 | suppressed |
| Carvedilol | Carvedilol | 11 | suppressed |
| Clotrimazole | Clotrimazole | 11 | 11 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Hailey Fe | Norethindrone-E.Estradiol-Iron | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $290.59 · 10 records | ABBVIE INC. | AIRSUPRA, Auvelity, Cologuard Collection Kit, ELIQUIS, NURTEC ODT, QULIPTA, UBRELVY | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error